uniQure Reports Positive 36-Month Phase I/II Data for AMT-130 in Huntington's Disease

summarizeResume

The positive 36-month data for AMT-130 represents a significant de-risking event for uniQure's lead program, positioning it closer to regulatory submission and potential commercialization. The statistically significant slowing of disease progression in Huntington's disease, a condition with no disease-modifying treatments, could be transformative for patients and a major value driver for the company. The ongoing progress in other pipeline assets and a robust cash position further strengthen the company's outlook. Investors should monitor the company's interactions with the FDA regarding the accelerated approval pathway and further clinical updates.

check_boxEvenements cles

• AMT-130 Shows Significant Efficacy

  High-dose AMT-130 demonstrated a statistically significant 75% reduction in disease progression (cUHDRS, p=0.003) and 60% reduction in Total Functional Capacity (TFC, p=0.033) at 36 months compared to an external control in Huntington's disease patients.

• Favorable Safety Profile for AMT-130

  The gene therapy remained generally well-tolerated with a manageable safety profile, reporting no new drug-related serious adverse events observed since December 2022.

• Advancing Regulatory Pathway

  uniQure plans to complete Chemistry, Manufacturing, and Controls (CMC) requirements for Biologics License Application (BLA) submission and engage with the FDA on an Accelerated Approval pathway for AMT-130 in 2026.

• Pipeline Progress

  The company reported encouraging early efficacy and safety data for AMT-260 in refractory mesial temporal lobe epilepsy (MTLE) and sustained therapeutic α-GAL levels for AMT-191 in Fabry disease.

auto_awesomeAnalyse

The positive 36-month data for AMT-130 represents a significant de-risking event for uniQure's lead program, positioning it closer to regulatory submission and potential commercialization. The statistically significant slowing of disease progression in Huntington's disease, a condition with no disease-modifying treatments, could be transformative for patients and a major value driver for the company. The ongoing progress in other pipeline assets and a robust cash position further strengthen the company's outlook. Investors should monitor the company's interactions with the FDA regarding the accelerated approval pathway and further clinical updates.